9
Clinical Trials associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)Prospective, Multicenter, Open, One-arm Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells
To evaluate the ORR (CR+PR) of R/R B-NHL subjects treated with BTKi+Anti-CD19 CAR T cells.
Prospective, Multicenter, Open, One-arm Clinical Study of Safety and Efficacy of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
To evaluate the CR rate of B-NHL subjects who achieved PR at intermediate assessment after first-line chemotherapy treated with autologous stem cell transplantation + Anti-CD19 CAR T cells.
Combination of humanized anti-CD19 CAR-T and anti-BCMA CAR-T versus autogolous hematopoietic stem cell transplantation for non-complete remission multiple myeloma: a single center, open-label, randomized controlled trial
Start Date01 Nov 2019 |
Sponsor / Collaborator- |
100 Clinical Results associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)
100 Translational Medicine associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)
100 Patents (Medical) associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)
100 Deals associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)